Eli Lilly to Acquire Merida Biosciences for Up to $2.875 Billion, Expanding into Autoimmune Antibody Degradation Therapy
nashnova research
Eli Lilly is paying up to $2.875 billion in cash for Merida Biosciences, gaining a therapy that selectively destroys disease-causing antibodies — a direct bet on precision autoimmune treatment.
What exactly is Lilly buying?
Merida Biosciences develops biologics that selectively degrade pathogenic autoantibodies — antibodies the immune system mistakenly produces against the body's own tissue.
In plain terms = the immune system sometimes attacks its own organs; Merida's technology removes only the "wrong" antibodies while leaving normal immunity intact.
The deal is worth up to $2.875 billion in cash, structured as upfront plus milestone payments, and is expected to close in Q4 2026.
How far along is the lead program?
Merida's main candidate is MER511, currently in Phase 1 clinical trials.
It targets Graves' disease — an autoimmune thyroid condition — and the thyroid eye disease it can trigger.
This means → the drug is still far from market. Phase 1 primarily tests safety and early efficacy; Phase 2 and Phase 3 still lie ahead.
Why is Lilly moving now?
Francisco Ramírez-Valle, Lilly's SVP of immunology research, said early Phase 1 data already show potential for improved efficacy and safety.
More importantly, Lilly sees the technology expanding beyond a single disease to a broader set of antibody-driven conditions.
This reflects Lilly's push to build a precision autoimmune pipeline beyond its GLP-1 franchise.
Is $2.875 billion justified — and who decides?
The deal uses an "upfront + milestone" structure, meaning most of the total price is paid only if clinical milestones are met.
In plain terms = Lilly is not betting the full sum at once; it spreads the risk across each critical development checkpoint.
Whether MER511 delivers efficacy and safety data in Phase 2 and Phase 3 will ultimately determine the final price tag and the return on this investment.
市场有风险，内容仅供研究参考，不构成投资建议。